Treatment of liproxstatin-1 reversed the inhibition of MM progression induced by LILRB1 deficiency in vivo (Fig. 3g–i), indicating that LILRB1 indeed promotes MM progression in vivo by inhibiting MM cell ferroptosis. The gene discussed is LILRB1; the disease is Miyoshi myopathy.